A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C

Hepatology

Volumn 26, Issue 5, 1997, Pages 1318-1321

  Pardo, Margarita ^a   Castillo, Inmaculada ^a   Oliva, Horacio ^b   Fernández Flores, Angel ^b   Bárcena, Rafael ^c   De Peuter, Maria Antje ^d   Carreño, Vicente ^a,b  

^a Fund El Estud Las Hepat Virales   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Chiron BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030716330     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260533     Document Type: Article

References (19)

1. Dienstag JL. Non-A, non-B hepatitis. Recognition, epidemiology and clinical features. Gastroenterology 1983;85:439-462.
2. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. New Engl J Med 1989;321:1501-1506.
3. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melmann M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. New Engl J Med 1989;321:1506-1510.
4. Gomez-Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreño V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 1990;11(S1):s63-67.
5. Oldham RK. In vivo effects of IL-2. J Biol Response Modif 1984;9:455-532.
6. Zhang SR, Salup RR, Urias PE, Twilley TA, Talmadge JE, Heberman RB, Willtrout RH. Augmentation of liver-associated NK activity and macrophage-mediated cytotoxicity following administration of biological response modifiers. Cancer Immunol Immunother 1986;21:19-25.
7. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumour cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-1841.
8. Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J Exp Med 1984;159:495-507.
9. Kakumu S, Fuji A, Yoshioka K, Tahara H, Ohtani Y, Hirofuji H, Murase K, et al. Pilot study of recombinant human interleukin-2 for chronic type B hepatitis. HEPATOLOGY 1988;8:487-492.
10. Onji M, Kondoh H, Norhke N, Yamaguchi S, Ogawa Y, Kumon I, Ohta Y. Effect of recombinant interleukin-2 on hepatitis B e antigen positive chronic hepatitis. Gut 1987;28:1648-1652.
11. Tilg H, Vogel W, Tratkiewicz J, Aulitzky WE, Herold M, Gruber M, Geissler D, et al. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. J Hepatol 1993;19:259-267.
12. Bach N, Schaffner F, Lin SC. High dose recombinant interleukin-2 for chronic viral hepatitis. Lancet 1989;103:281.
13. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY, 1994;19:1513-19.
14. Castillo I, Bartolomé J, Navas S, Gonzalez S, Herrero M, Carreño V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. HEPATOLOGY 1994;19:1342-1346.
15. Gerber MA. Pathobiologic effects of hepatitis C. J Hepatol 1995;22 (S1): S83-86.
16. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, Eichenlaub D, et al. Possible mechanism involving T-lyphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346:1006-1007.
17. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, Rumi MG, et al. Different clinical behaviors of acute hepatitis C infection are associated with different vigor of the antiviral cell-mediated immune response. J Clin Invest 1996;98:706-714.
18. Tsai S-L, Liaw Y-F, Chen M-H, Huang C-Y, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. HEPATOLOGY 1997;25:449-458.
19. Sleijfer DTh, Janssen RAJ, Buter J, de Vries EGE, Willemse PHB, Mulder NH. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992;10:1119-1123.